Vertis , a precision medical technology company based on proteomics, announced on the 15th that it has signed a business agreement (MOU) with Cosmax , a global cosmetics ODM (research, development, and production) company, for collaboration in skin proteomics analysis research.
Through this MOU, Bertis and Cosmax plan to pursue comprehensive cooperation in joint business areas such as ▲academic exchange related to skin protein analysis technology ▲joint development of skin biomarker panels ▲development, production, and commercialization of cosmetic materials and formulations.
Skin analysis using proteomics technology is a technology that precisely analyzes proteins expressed in skin tissue or cells to identify physiological changes in the skin or biological responses to external stimuli. Through this, proteins related to skin aging, damage, regeneration, and troubles can be accurately identified, and can be used for personal skin diagnosis and customized cosmetics development.
As the world’s No. 1 cosmetics ODM company, Cosmax possesses the industry’s highest level of biological resource utilization technology and has been leading the anti-aging cosmetics field, such as commercializing the world’s first skin microbiome cosmetics in 2019. Starting with establishing skin protein analysis technology, the two companies plan to promote the development of skin protein types and diagnostic software by aging cause through database accumulation.
“Vertis has unrivaled technology and know-how in discovering biomarkers for cancer, aging, and various major diseases using proteomics technology, and developing diagnostic and analysis solutions based on these,” said Seungman Han, CEO of Vertis. “Through research collaboration with Cosmax, we hope to secure skin protein analysis technology and expand the scope of proteomics technology implementation to the field of customized skin aging management.”
Meanwhile, Vertis is leading the commercialization of proteomics technology based on its core technology system, ProteoID, which covers everything from protein data analysis to commercialization of products and services. In 2019, it commercialized the world's first proteomics-based breast cancer early diagnosis blood test, MASTOCHECK®, and through its pan-omics integrated analysis solution, PASS (Pan-omics Analysis Service & Solution), it provides customized analysis results specialized for the purposes of each client, such as biotechs developing new modality drugs, CDMO companies, as well as basic R&D research.
- See more related articles
You must be logged in to post a comment.